Clinuvel Pharmaceuticals Ltd (CLVLF) stock analysis
Close on Oct 19, 2026Market cap $254.66MP/E 11.0Yield –
StockData Score
Prices as of Nov 6, 2026How the score works
Mixed9 of 30 checks passed
Clinuvel Pharmaceuticals passes 9 of the 30 checks behind our score; 19 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 1/6
- Past performance
- 3/6
- Financial health
- 5/6
- Dividend
- 0/6
What stands out
Return on capital over 10%
Return on invested capital was 153%, above the 10% that usually covers the cost of capital.
No debt
Clinuvel Pharmaceuticals has no borrowings on its latest balance sheet.
Interest well covered
No meaningful interest expense to cover.
Debt covered by cash flow
There is no debt to cover.
What to watch
Growing slower than the industry
Revenue grew 5.2% over the last twelve months; the Industrials median is 7.8%.
No dividend
Clinuvel Pharmaceuticals has not paid a dividend in the last twelve months.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B against the industry
Needs positive book value.
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.
Growth1/6
Revenue growth over 3 years
Needs three years of positive revenue.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing slower than the industry
Revenue grew 5.2% over the last twelve months; the Industrials median is 7.8%.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin improving
Gross margin was 82.9% over the last twelve months, against 81.2% a year earlier.
Past performance3/6
Return on equity
Needs positive equity and five years of results.
Return on capital over 10%
Return on invested capital was 153%, above the 10% that usually covers the cost of capital.
Return on equity above the industry
Clinuvel Pharmaceuticals's return on equity of 13.4% is above the Industrials median of 5.9%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin against its history
Needs five years of revenue and net income.
Net margin above the industry
Clinuvel Pharmaceuticals's net margin of 36.0% is above the Industrials median of 2.6%.
Financial health5/6
No debt
Clinuvel Pharmaceuticals has no borrowings on its latest balance sheet.
Debt not rising
With no debt today, leverage cannot have risen.
Debt covered by cash flow
There is no debt to cover.
Interest well covered
No meaningful interest expense to cover.
Short-term assets cover short-term debts
Current assets are 14.72 times current liabilities.
Bankruptcy risk (Altman Z)
Needs market value, working capital and retained earnings.
Dividend0/6
No dividend
Clinuvel Pharmaceuticals has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itWe don't publish a fair value for Clinuvel Pharmaceuticals. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
High risk
- Average value traded per day
- $31.61K
- Value traded per 1% price move
- $10.84K
Downside
Medium risk
- Typical loss in a bad month
- 20.8%
- Volatility (annualized)
- 49%
- Sharpe ratio, 1 year
- -0.68
- Beta to the S&P 500 (5Y)
- 0.81
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2023 to 2026
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +5.2% | – | – | – | |
| Gross profit | +7.5% | – | – | – | |
| Operating income | +5.3% | – | – | – | |
| Net income | +0.2% | – | – | – | |
| EPS, diluted | 0.0% | – | – | – | |
| Free cash flow | -56.3% | – | – | – |
Returns and balance sheet
4 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2023 | FY2023 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 13.4% | |
| Current ratio | – | – | 14.72 | |
| Capex to revenue | – | – | 1.6% | |
| Diluted shares | – | – | 51M |
Cash use needs five years of cash flow figures
Clinuvel Pharmaceuticals does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | 36.0% | 0.34× | 1.10× | 13.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
- ProfitableNet income above zero$23.18M
- Cash generatingOperating cash flow above zero$12.91M
- Return on assets improvedROA up on the prior year– → 13.1%
- Earnings backed by cashOperating cash flow above net income$12.91M vs $23.18M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose9.68 → 14.72
- No dilutionShare count did not rise50M → 51M
- Gross margin improvedGross margin up on the prior year81.16% → 82.93%
- More efficientAsset turnover rose– → 0.36
See a number that looks wrong?